Recursion Pharmaceuticals, Inc.

RXRX · Healthcare · Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating techn…

Recursion Pharmaceuticals, Inc. (RXRX), in the Healthcare sector, has 25 disclosed filings on Paydirt over the trailing twelve months from 4 corporate insiders: 0 purchases and 25 sales, 2 filed past the deadline. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Nov 3 and filed Nov 4. The most active filer was Christopher Gibson with 13 filings. Data as of Nov 8 2026.

Add to watchlist

Filings, ttm

0 buys · 25 sells · 2 late

Traders, ttm

4 insiders

Volume, ttmiDollar value disclosed in the window

$6.8M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Nov 3

Filed Nov 4

ADViAverage daily dollar volume

$67.5M

market data

Share price · 12M

$3.52 (-22.0%)

Adjusted for splits and dividends.

Volume by month

Buys $0 Sells $15.1M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed · past 24 months

Christopher Gibson Director 26 filings · 0 buys, 26 sales BB

Blake Borgeson Director 10 filings · 0 buys, 10 sales NK

Najat Khan Chief R&D Commercial Officer 2 filings · 0 buys, 2 sales RH

Robert Hershberg Director 1 filing · 0 buys, 1 sale MS

Michael Secora Chief Financial Officer 1 filing · 0 buys, 1 sale

Recent filings

Blake BorgesonSALE Director $155K
40,000 sh × $3.88
Exec Nov 3
Filed Nov 4 · 5:12 PM ET Blake BorgesonSALE Director $242K
50,000 sh × $4.84
Exec Oct 6
Filed Oct 7 · 6:08 PM ET Robert HershbergSALE Director $125K
25,000 sh × $5.00
Exec Oct 6
Filed Oct 7 · 6:08 PM ET Blake BorgesonSALE Director $100K
30,000 sh × $3.34
Exec Sep 1
Filed Sep 2 · 6:01 PM ET Blake BorgesonSALE Director $158K
40,000 sh × $3.96
Exec Jul 7
Filed Jul 9 · 6:04 PM ET Christopher GibsonSALE Director $145K
40,000 sh × $3.62
Exec Jun 5
Filed Jun 5 · 5:30 PM ET Blake BorgesonSALE Director $110K
30,000 sh × $3.68
Exec Jun 2
Filed Jun 4 · 5:30 PM ET Christopher GibsonSALE Director $123K
40,000 sh × $3.08
Exec May 22
Filed May 27 · 5:30 PM ET Christopher GibsonSALE Director $135K
40,000 sh × $3.37
Exec May 7
Filed May 8 · 5:30 PM ET Blake BorgesonSALE Director $106K
30,000 sh × $3.52
Exec May 5
Filed May 7 · 5:30 PM ET Christopher GibsonSALE Director $144K
40,000 sh × $3.61
Exec Apr 22
Filed Apr 24 · 5:30 PM ET Christopher GibsonSALE Director $124K
40,000 sh × $3.10
Exec Apr 7
Filed Apr 8 · 5:30 PM ET Christopher GibsonSALE Director $130K
40,000 sh × $3.25
Exec Mar 23
Filed Mar 25 · 5:30 PM ET Blake BorgesonSALE Director $588K
170,000 sh × $3.46
Exec Mar 3
Filed Mar 4 · 5:30 PM ET Christopher GibsonSALE Director $138K
40,000 sh × $3.46
Exec Feb 19
Filed Feb 19 · 5:30 PM ET Blake BorgesonSALE Director $924K
220,000 sh × $4.20
Exec Feb 3
Filed Feb 6 · 5:30 PM ET † Christopher GibsonSALE Director $165K
40,000 sh × $4.12
Exec Feb 4
Filed Feb 6 · 5:30 PM ET Christopher GibsonSALE Director $179K
40,000 sh × $4.47
Exec Jan 20
Filed Jan 22 · 5:30 PM ET Blake BorgesonSALE Director $959K
220,000 sh × $4.36
Exec Jan 6
Filed Jan 8 · 5:30 PM ET Christopher GibsonSALE Director $170K
40,000 sh × $4.25
Exec Jan 5
Filed Jan 7 · 5:30 PM ET Najat KhanSALE Chief R&D Commercial Officer $549K
124,403 sh × $4.41
Exec Dec 22 2025
Filed Dec 29 2025 · 5:30 PM ET † Christopher GibsonSALE Chief Executive Officer $180K
40,000 sh × $4.50
Exec Dec 19 2025
Filed Dec 19 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $185K
40,000 sh × $4.63
Exec Dec 4 2025
Filed Dec 5 2025 · 5:30 PM ET Blake BorgesonSALE Director $961K
220,000 sh × $4.37
Exec Dec 2 2025
Filed Dec 4 2025 · 5:30 PM ET Christopher GibsonSALE Chief Executive Officer $166K
40,000 sh × $4.16
Exec Nov 19 2025
Filed Nov 19 2025 · 5:30 PM ET